Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension
SY Smith-Apeldoorn, JKE Veraart, J Kamphuis… - Molecular …, 2024 - nature.com
About one-third of patients with depression do not achieve adequate response to current
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension
S Smith-Apeldoorn, JKE Veraart, J Kamphuis, J Spijker… - 2023 - researchsquare.com
About one-third of patients with depression do not achieve adequate response to current
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.
SY Smith-Apeldoorn, JKE Veraart, J Kamphuis… - Molecular …, 2024 - europepmc.org
About one-third of patients with depression do not achieve adequate response to current
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension
SY Smith-Apeldoorn, JKE Veraart, J Kamphuis… - Molecular …, 2024 - research.rug.nl
About one-third of patients with depression do not achieve adequate response to current
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension
SY Smith-Apeldoorn, JKE Veraart… - Molecular … - pubmed.ncbi.nlm.nih.gov
About one-third of patients with depression do not achieve adequate response to current
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension
S Smith-Apeldoorn, J Veraart, J Kamphuis, J Spijker… - 2023 - europepmc.org
About one-third of patients with depression do not achieve adequate response to current
treatment options. Although intravenous and intranasal administrations of (es) ketamine …
treatment options. Although intravenous and intranasal administrations of (es) ketamine …